MEDSIR’s PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Newswise — JERSEY CITY, N.J., June 2, 2023 /PRNewswire/ — MEDSIR announced today the positive results of the PHERGain trial. This study is the first to use an adaptive design that tailors treatment…
Read more MEDSIR’s PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer